CSPM EDP Sciences logo
Access to submission and peer review system
Search
Menu
All issues Volume 3 (2022) Vis Cancer Med, 3 (2022) 4 References
Open Access
Issue
Vis Cancer Med
Volume 3, 2022
Article Number 4
Number of page(s) 4
DOI https://doi.org/10.1051/vcm/2022005
Published online 21 October 2022
  1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021;71:209–249. [CrossRef] [PubMed] [Google Scholar]
  2. Zheng RS, Zhang SW, Zeng HM, et al. Cancer incidence and mortality in China, 2016. Journal of the National Cancer. 2022;2(1):1–9. [CrossRef] [PubMed] [Google Scholar]
  3. Xie S-H, Huang R-Q, Liu Y-L, et al. An increase in early cancer detection rates at a single cancer center: Experiences from Sun Yat-sen University Cancer Center. Visualized Cancer Medicine. 2022;3:1. [CrossRef] [EDP Sciences] [Google Scholar]
  4. de Sousa VML, Carvalho L, Heterogeneity in lung cancer. Pathobiology. 2018;85:96–107. [CrossRef] [PubMed] [Google Scholar]
  5. Shah DR, Masters GA, Precision medicine in lung cancer treatment. Surg Oncol Clin N Am. 2020;29(1):15–21. [CrossRef] [PubMed] [Google Scholar]
  6. Melosky B, Wheatley-Price P, Juergens RA, et al. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. Lung Cancer. 2021;160:136–151. [CrossRef] [PubMed] [Google Scholar]
  7. Hou H, Zhu H, Zhao H, et al. Comprehensive molecular characterization of young Chinese patients with lung adenocarcinoma identified a distinctive genetic profile. Oncologist. 2018;23(9):1008–1015. [CrossRef] [PubMed] [Google Scholar]
  8. Zhang C, Jiang M, Zhou N, et al. Use tumor suppressor genes as biomarkers for diagnosis of non-small cell lung cancer. Sci Rep. 2021;11(1):3596. [CrossRef] [PubMed] [Google Scholar]
  9. Zhou N, Zhang C, Liu D, et al. Apatinib in combination with S-1 as first-line treatment in patients with advanced metastatic gastric cancer: results from an open, exploratory, single-arm, phase II Trial. Oncologist. 2021;26(3):e374–e381. [CrossRef] [PubMed] [Google Scholar]
  10. Zhou N, Jiang M, Li T, et al. Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study. Lung Cancer. 2021;160:111–117. [CrossRef] [PubMed] [Google Scholar]
  11. Hou H, Qin K, Liang Y, et al. Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC. Cancer Management and Research. 2019;11:5665–5675. [CrossRef] [Google Scholar]
  12. Zhao D, Zhang C, Jiang M, et al. Survival-associated alternative splicing signatures in non-small cell lung cancer. Aging (Albany NY). 2020;12(7):5878–5893. [CrossRef] [PubMed] [Google Scholar]
  13. Jiang M, Zhang C, Liu D, et al. Influence and mechanism of lung cavitation development on antiangiogenic therapy. Translational Lung Cancer Research. 2019;8(4):500–512. [CrossRef] [PubMed] [Google Scholar]
  14. Wang L, Qu J, Liang Y, et al. Identification and validation of key genes with prognostic value in non-small-cell lung cancer via integrated bioinformatics analysis. Thoracic Cancer. 2020;11(4):851–866. [CrossRef] [PubMed] [Google Scholar]
  15. Zhou N, Zhang CT, Lv HY, et al. Concordance study between IBM Watson for Oncology and clinical practice for patients with cancer in China. Oncologist. 2019;24(6):812–819. [CrossRef] [PubMed] [Google Scholar]
  16. Zhang X, Fang B, Mohan R, et al. Coxsackie-adenovirus receptor as a novel marker of stem cells in treatment-resistant non-small cell lung cancer. Radiotherapy and Oncology. 2012;105(2):250–257. [CrossRef] [PubMed] [Google Scholar]
  17. Dong OM, Poonnen PJ, Winski D, et al. Cost-effectiveness of tumor genomic profiling to guide first-line targeted therapy selection in patients with metastatic lung adenocarcinoma. Value Health. 2022;25(4):582–594. [CrossRef] [PubMed] [Google Scholar]
  18. Liu G, Kang S, Wang X, et al. Cost-effectiveness analysis of atezolizumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer with different PD-L1 expression status. Frontiers in Oncology. 2021;11:669195. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.